Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Announces Details Of Its Ranbaxy Acquisition

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Daiichi Sankyo Aug. 11 announced details of its tender offer for Ranbaxy Laboratories, effective Aug. 16 through Sept. 4

You may also be interested in...



As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened

Indian generics manufacturer Ranbaxy Laboratories' tangle with U.S. FDA is persisting and will likely impact U.S. sales in 2009

As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened

Indian generics manufacturer Ranbaxy Laboratories' tangle with U.S. FDA is persisting and will likely impact U.S. sales in 2009

Daiichi Sankyo’s Deal With Ranbaxy Hits A Snag

MUMBAI - There is trouble for Japanese drug maker Daiichi Sankyo's takeover proposal of India's largest pharmaceutical company Ranbaxy as India's stock market regulator, the Securities and Exchange Board of India, has rejected a plea from Ranbaxy promoters to execute the 34.8 percent stake sale to Daiichi Sankyo through live-market transactions

Related Content

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel